drugset / Trial / NCT01031953
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
Phase 1/2
Terminated
34 enrolled
OHSU Knight Cancer Institute
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care
Summary
RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying the side effects of fosaprepitant dimeglumine and to see how well it works in treating patients with nausea and vomiting caused by chemotherapy.
Timeline
- Start
- 2008-08
- Primary completion
- 2013-02
- Completion
- 2013-02
Outcome
Outcome not reported
Stopped (Enrollment): “Drug contract timelines and inadequate enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosaprepitant | Other / unclassified | 150 mg | Intravenous |
Indications
No indication recorded.